Zacks Research Issues Pessimistic Forecast for TMO Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Analysts at Zacks Research dropped their Q4 2024 earnings per share (EPS) estimates for shares of Thermo Fisher Scientific in a research note issued to investors on Tuesday, November 12th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $5.76 per share for the quarter, down from their prior forecast of $5.95. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $21.69 per share. Zacks Research also issued estimates for Thermo Fisher Scientific's Q1 2025 earnings at $5.40 EPS, Q2 2025 earnings at $5.65 EPS, Q3 2025 earnings at $5.82 EPS, Q4 2025 earnings at $6.21 EPS, Q1 2026 earnings at $6.75 EPS, Q2 2026 earnings at $7.03 EPS and Q3 2026 earnings at $6.78 EPS.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts' consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion for the quarter, compared to analysts' expectations of $10.63 billion. During the same quarter last year, the company earned $5.69 EPS. The company's revenue for the quarter was up .2% compared to the same quarter last year.

A number of other analysts also recently commented on TMO. Bernstein Bank boosted their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a "market perform" rating in a research note on Tuesday, October 22nd. Redburn Atlantic initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They issued a "buy" rating and a $680.00 price target for the company. Sanford C. Bernstein dropped their target price on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a "market perform" rating on the stock in a report on Thursday, October 24th. Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an "overweight" rating in a report on Friday, September 20th. Finally, JPMorgan Chase & Co. increased their price objective on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an "overweight" rating in a research report on Friday, September 20th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $649.33.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded down $8.88 during trading hours on Thursday, hitting $533.02. 1,747,993 shares of the company traded hands, compared to its average volume of 1,462,920. The firm's 50-day simple moving average is $589.87 and its two-hundred day simple moving average is $583.04. The firm has a market cap of $203.88 billion, a P/E ratio of 33.78, a P/E/G ratio of 3.57 and a beta of 0.79. Thermo Fisher Scientific has a 1-year low of $463.99 and a 1-year high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be paid a $0.39 dividend. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific's dividend payout ratio is currently 9.78%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 9,000 shares of the firm's stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $552.86, for a total value of $4,975,740.00. Following the completion of the sale, the chief executive officer now owns 14,608 shares in the company, valued at approximately $8,076,178.88. This trade represents a 38.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the sale, the executive vice president now directly owns 16,663 shares of the company's stock, valued at $9,333,946.08. This represents a 1.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 9,000 shares of the business's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $552.86, for a total value of $4,975,740.00. Following the completion of the transaction, the chief executive officer now owns 14,608 shares of the company's stock, valued at $8,076,178.88. This represents a 38.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,150 shares of company stock valued at $20,651,865. 0.34% of the stock is owned by insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of institutional investors have recently added to or reduced their stakes in the company. Peterson Financial Group Inc. acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth about $27,000. Signature Resources Capital Management LLC lifted its position in shares of Thermo Fisher Scientific by 318.2% in the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock valued at $25,000 after buying an additional 35 shares during the last quarter. New Millennium Group LLC bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $29,000. Stephens Consulting LLC raised its stake in Thermo Fisher Scientific by 116.0% in the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock valued at $30,000 after acquiring an additional 29 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter valued at $32,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.